Download an extract of the data-rich resource: Biomedtracker’s Q3 2018 Outlook Report. This latest installment in Biomedtracker’s ongoing quarterly reports contains expected drug catalyst predictions, important clinical and … Continue Reading Q3 2018 Outlook Report
This eBook is a celebration of the innovative efforts driving cancer research forward. Download this eBook to: Discover the diverse and innovative projects propelling the Cancer Moonshot forward Read thought-provoking … Continue Reading Innovations in Oncology: The Cancer Moonshot and Beyond [eBook]
Discover why Brexit Won’t Delay Drug Approvals. Plus how the #UK & the #EuropeanMedicinesAgency could work together informally after #Brexit. Download the full article pack & learn more: Brexit Implications for Pharma Article Pack V2 … Continue Reading Brexit Implications for Pharma Article Pack
Status Quo or No? As Informa Pharma Intelligence has done for the past three years, this analysis examines the landscape of industry-sponsored clinical trials completed during 2017, of which there were … Continue Reading 2017 Completed Trials report
Innovation in the pharmaceutical industry has never been more exciting, and complicated. Disruptive technologies, such as artificial intelligence and digital health tools, and advanced therapeutic modalities including cell and gene … Continue Reading Pharma Asset Insights report
The last twelve months have seen many advances within the field of genomics. The price of sequencing and analysis has continued to drop dramatically and accuracy gets better with … Continue Reading Clinical Genomics 101: 2018 Edition
Cancer is one of the oldest diseases known to human society, and recently it’s the development of next-generation sequencing and a stronger understanding of genetic mutations that have driven … Continue Reading Cancer Genomics 101: 2018 Edition
Developing new drugs isn’t easy. Only around 10% of compounds that reach preclinical development will ever be tested in a human being and for every drug that reaches the … Continue Reading Drug Development 101: 2018 Edition
Οι εταιρείες βιοεπιστημών κινδυνεύουν να περιθωριοποιηθούν από τις εταιρείες τεχνολογίας και τους νεοεισερχόμενους στην αγορά παίκτες, σύμφωνα με τη νέα έκθεση της EY, Progressions 2018 Life Sciences 4.0: Securing value through data–driven platforms. Η έκθεση αναφέρει ότι … Continue Reading «Καμπανάκι» για τις εταιρίες βιοεπιστημών
b324212e-f8ed-4534-8faf-21cfd83cedc2_KNect365CellandGeneTherapiesReport2018 Πηγή
Worldwide orphan drug sales are forecasted to grow at a CAGR of 11% from 2018-2024 Our 2018 Orphan Drug Report shows continuing unmet medical need is set to fuel the … Continue Reading EVALUATEPHARMA ORPHAN DRUG REPORT 2018
PipelineReport-Brand-Drugs
The Top 15 Best Selling Cancer Drugs in 2022
mrx-report-fall17_web-optimized
ML_CART_Note_V10
epv-cart16
